Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Precipio Inc (PRPO)

Precipio Inc (PRPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,500
  • Shares Outstanding, K 1,482
  • Annual Sales, $ 15,200 K
  • Annual Income, $ -5,850 K
  • EBIT $ -6 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.41
  • Price/Sales 0.63
  • Price/Cash Flow N/A
  • Price/Book 0.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +4.78%
on 10/14/24
7.00 -10.00%
on 10/10/24
-0.41 (-6.11%)
since 10/01/24
3-Month
4.90 +28.57%
on 08/06/24
7.20 -12.50%
on 08/22/24
+1.12 (+21.62%)
since 08/01/24
52-Week
4.31 +46.17%
on 07/12/24
8.74 -27.94%
on 11/10/23
-1.37 (-17.86%)
since 11/01/23

Most Recent Stories

More News
Precipio Expands Bloodhoundâ„¢ MPN Panel by Adding CALR Mutation Subtyping

PRPO : 6.30 (-1.72%)
Zacks Initiates Coverage of Precipio With Outperform Recommendation

Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an "Outperform" recommendation to the company's shares. This bullish stance reflects the company's path to profitability...

PRPO : 6.30 (-1.72%)
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development

Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors ...

PRPO : 6.30 (-1.72%)
Precipio Announces Second Quarter Shareholder Update Call

Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST...

PRPO : 6.30 (-1.72%)
Precipio to distribute HemeScreen® through Fisher Healthcare channel

Agreement Enhances Precipio’s Product Reach to US Laboratories...

PRPO : 6.30 (-1.72%)
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote

Meeting Adjourned, new meeting set for July 5th at 10am EDT...

PRPO : 6.30 (-1.72%)
Keith Meadors Joins Precipio to Lead its Products Division

Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations...

PRPO : 6.30 (-1.72%)
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe

This Regulatory Approval Opens the Company’s Reach to the European Market...

PRPO : 6.30 (-1.72%)
Precipio Signs First IV-Cell Customer Agreement

Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential...

PRPO : 6.30 (-1.72%)
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its...

PRPO : 6.30 (-1.72%)

Business Summary

Precipio Inc. has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class...

See More

Key Turning Points

3rd Resistance Point 6.70
2nd Resistance Point 6.56
1st Resistance Point 6.49
Last Price 6.30
1st Support Level 6.28
2nd Support Level 6.14
3rd Support Level 6.07

See More

52-Week High 8.74
Fibonacci 61.8% 7.05
Fibonacci 50% 6.53
Last Price 6.30
Fibonacci 38.2% 6.00
52-Week Low 4.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar